You are here

USITC Institutes Section 337 Investigation of Certain Flocked Swabs, Products Containing Flocked Swabs, and Methods of Using Same

August 27, 2021
News Release 21-210
Inv. No. 337-TA-1279
Contact: Peg O'Laughlin, 202-205-1819
USITC Institutes Section 337 Investigation of Certain Flocked Swabs, Products Containing Flocked Swabs, and Methods of Using Same

The U.S. International Trade Commission (USITC) has voted to institute an investigation of certain flocked swabs, products containing flocked swabs, and methods of using same.  The products at issue in the investigation are described in the Commission’s notice of investigation.

The investigation is based on a complaint filed by Copan Italia S.p.A of Brescia, Italy, and Copan Industries, Inc., of Aguadilla, Puerto Rico, on July 9, 2021.  Supplements to the complaint were filed on August 16, 2021; August 19, 2021; and August 23, 2021.  The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930 in the importation into the United States and sale of certain flocked swabs, products containing flocked swabs, and methods of using same that infringe patents asserted by the complainants.  The complainants request that the USITC issue a general exclusion order, or in the alternative a limited exclusion order, and cease and desist orders. 

The USITC has identified the following as respondents in this investigation:

Han Chang Medic of Chungnam, Republic of Korea;
Wuxi NEST Biotechnology Co., Ltd. of Wuxi, Jiangsu, China;
NEST Scientific Inc. of Rahway, NJ;
NEST Scientific USA of Rahway, NJ;
Miraclean Technology Co., Ltd., of Shenzhen, Guangdong, China;
Vectornate Korea Ltd. of Jangseong, Jeonnam, Republic of Korea;
Innovative Product Brands, Inc., of Highland, CA;
Thomas Scientific, Inc., of Swedesboro, NJ;
Thomas Scientific, LLC, of Swedesboro, NJ;
Stellar Scientific, LLC, of Owings Mills, MD;
Cardinal Health, Inc., of Dublin, OH;
Ksl Biomedical, Inc., of Williamsville, NY;
Ksl Diagnostics, Inc., of Williamsville, NY;
Jiangsu Changfeng Medical Industry Co., Ltd., of Yangzhou, Jiangsu, China;<
No Borders Dental Resources, Inc., dba MediDent Supplies, of Queen Creek, AZ;<
BioTeke Corporation (Wuxi) Co., Ltd., of Wuxi, Jiangsu, China;
Fosun Pharma USA Inc. of Princeton, NJ;<
Hunan Runmei Gene Technology Co., Ltd., of Changsha, Hunan, China;
VWR International, LLC, of Radnor, PA; and
Slmp, LLC, dba StratLab Medical Products of McKinney, TX.

By instituting this investigation (337-TA-1279), the USITC has not yet made any decision on the merits of the case.  The USITC’s Chief Administrative Law Judge will assign the case to one of the USITC’s administrative law judges (ALJ), who will schedule and hold an evidentiary hearing.  The

ALJ will make an initial determination as to whether there is a violation of section 337; that initial determination is subject to review by the Commission.

The USITC will make a final determination in the investigation at the earliest practicable time.  Within 45 days after institution of the investigation, the USITC will set a target date for completing the investigation.  USITC remedial orders in section 337 cases are effective when issued and become final 60 days after issuance unless disapproved for policy reasons by the U.S. Trade Representative within that 60-day period.

# # #